You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDronedarone
Accession NumberDB04855
TypeSmall Molecule
GroupsApproved
DescriptionDronedarone is a sinus rhythm controller for management of paroxysmal or persistent atrial fibrillation. Classified as a Class III antiarrhythmic but displays properties of all four Vaughan-Williams classes, dronedarone blocks a multitude of channels (sodium, potassium, calcium), and demonstrates antiadrenergic properties. Chemically, it is a benzofuran derivative. FDA approved on July 1, 2009.
Structure
Thumb
Synonyms
Multaq
N-(2-Butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide
N-(2-Butyl-3-(P-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide
SR 33589
SR 33589b
External Identifiers
  • SR33589
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MultaqTablet, film coated400 mgOralSanofi Aventis Groupe2009-11-26Not applicableEu
MultaqTablet, film coated400 mg/1OralSanofi Aventis U.S. Llc2009-07-01Not applicableUs
MultaqTablet400 mgOralSanofi Aventis Canada Inc2009-09-28Not applicableCanada
MultaqTablet, film coated400 mgOralSanofi Aventis Groupe2009-11-26Not applicableEu
MultaqTablet, film coated400 mg/1OralSanofi Winthrop Industries2009-07-01Not applicableUs
MultaqTablet, film coated400 mgOralSanofi Aventis Groupe2009-11-26Not applicableEu
MultaqTablet, film coated400 mg/1OralPhysicians Total Care, Inc.2010-02-23Not applicableUs
MultaqTablet, film coated400 mgOralSanofi Aventis Groupe2009-11-26Not applicableEu
MultaqTablet, film coated400 mg/1OralCardinal Health2009-07-01Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Dronedarone Hydrochloride
141625-93-6
Thumb
  • InChI Key: DWKVCQXJYURSIQ-UHFFFAOYSA-N
  • Monoisotopic Mass: 592.273770957
  • Average Mass: 593.217
DBSALT000061
Categories
UNIIJQZ1L091Y2
CAS number141626-36-0
WeightAverage: 556.756
Monoisotopic: 556.297093218
Chemical FormulaC31H44N2O5S
InChI KeyZQTNQVWKHCQYLQ-UHFFFAOYSA-N
InChI
InChI=1S/C31H44N2O5S/c1-5-8-12-29-30(27-23-25(32-39(4,35)36)15-18-28(27)38-29)31(34)24-13-16-26(17-14-24)37-22-11-21-33(19-9-6-2)20-10-7-3/h13-18,23,32H,5-12,19-22H2,1-4H3
IUPAC Name
N-(2-butyl-3-{4-[3-(dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl)methanesulfonamide
SMILES
CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2
Pharmacology
IndicationManagement of paroxysmal or persistent atrial fibrillation via restoration of normal sinus rhythm.
Structured Indications
PharmacodynamicsDronedarone is a non-iodinated benzofuran derivative for the management of paroxysmal or persistent atrial fibrillation. Dronedarone inhibits human atrial sodium currents (INa) in a dose dependent manner in which a concentration of 0.3 μM is sufficient to completely inhibit INa. Chemically it is related to amiodarone, a popular antiarrhythmic the use of which is limited to toxicity due its high iodine content (pulmonary fibrosis, thyroid disease) as well as by liver disease. Dronedarone lacks the iodine, and is expected to have less toxicity, yet it displays amiodarone-like class III antiarrhytmic activity in vitro and in clinical trials. Despite this advantage over amiodarone, clinical trials of dronedarone have shown that it may increase risk of stroke and mortality from cardiovascular causes and arrhythmia. Furthermore, amiodarone more potently effects action potential and refractory periods than dronedarone.
Mechanism of actionThe antiarrhythmic effect of dronedarone may be due to at least two major actions. It prolongs the duration of action potential and refractory period in myocardial tissue via inhibition of sodium and potassium channels. Via inhibition of calcium channels and blockage of beta1-adrenergic receptors, a decrease in AV conduction and sinus node function can be observed. Dronedarone can also cause an increase in blood pressure by inhibition of alpha1-adrenergic receptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Alpha-1A adrenergic receptorProteinunknown
antagonist
HumanP35348 details
Alpha-1B adrenergic receptorProteinunknown
antagonist
HumanP35368 details
Alpha-1D adrenergic receptorProteinunknownNot AvailableHumanP25100 details
Alpha-2A adrenergic receptorProteinunknownNot AvailableHumanP08913 details
Alpha-2B adrenergic receptorProteinunknownNot AvailableHumanP18089 details
Alpha-2C adrenergic receptorProteinunknownNot AvailableHumanP18825 details
Beta-1 adrenergic receptorProteinunknownNot AvailableHumanP08588 details
Potassium voltage-gated channel subfamily H member 2ProteinunknownNot AvailableHumanQ12809 details
Voltage-dependent L-type calcium channel subunit alpha-1CProteinunknownNot AvailableHumanQ13936 details
Voltage-dependent L-type calcium channel subunit alpha-1DProteinunknownNot AvailableHumanQ01668 details
Voltage-dependent L-type calcium channel subunit alpha-1FProteinunknownNot AvailableHumanO60840 details
Voltage-dependent L-type calcium channel subunit alpha-1SProteinunknownNot AvailableHumanQ13698 details
Voltage-dependent L-type calcium channel subunit beta-1ProteinunknownNot AvailableHumanQ02641 details
Voltage-dependent L-type calcium channel subunit beta-2ProteinunknownNot AvailableHumanQ08289 details
Voltage-dependent L-type calcium channel subunit beta-3ProteinunknownNot AvailableHumanP54284 details
Voltage-dependent L-type calcium channel subunit beta-4ProteinunknownNot AvailableHumanO00305 details
Sodium channel protein type 1 subunit alphaProteinunknown
inhibitor
HumanP35498 details
Potassium channel subfamily K member 2Proteinunknown
inhibitor
HumanO95069 details
Related Articles
AbsorptionBecause of presystemic first pass metabolism the absolute bioavailability of dronedarone without food is low, about 4%. It increases to approximately 15% when dronedarone is administered with a high fat meal. After oral administration in fed conditions, peak plasma concentrations of dronedarone and the main circulating active metabolite (N-debutyl metabolite) are reached within 3 to 6 hours. After repeated administration of 400 mg twice daily, steady state is reached within 4 to 8 days of treatment. The steady state Cmax and exposure of the main N-debutyl metabolite is similar to that of the parent compound.
Volume of distribution

When intravenously administered, the volume of distribution is 1400 L.

Protein bindingDronedarone and its N-debutyl metabolite is >98% protein bound - mainly to albumin.
Metabolism

Majority of dronedarone is eliminated by first-pass metabolism in the liver by CYP3A4 enzymes (>84%). Dronedarone is also metabolized by CYP2D6 to a lesser extent. N-DBD is its active metabolite (1/10 to 1/3 potency of dronedarone) which can penetrate the blood-brain barrier, placenta, and is excreted in breast milk. However, it does not significantly accumulate in plasma or tissue.

Route of elimination6% of the dose was excreted in the urine, mainly as metabolites (no unchanged compound excreted in urine), and 84% was excreted in feces, mainly as metabolites.
Half lifeElimination half-life: 13-19 hours
Clearance

Plasma clearance = 130-150 L/h.

ToxicityMost common adverse reactions (≥2%) are diarrhea, nausea, abdominal pain, vomiting, and asthenia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Dronedarone.Experimental, Illicit
AbirateroneThe serum concentration of Dronedarone can be increased when it is combined with Abiraterone.Approved
AcebutololDronedarone may increase the bradycardic activities of Acebutolol.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Dronedarone.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Dronedarone.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Dronedarone.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Dronedarone.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Dronedarone.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Dronedarone.Approved
AjmalineThe metabolism of Ajmaline can be decreased when combined with Dronedarone.Approved
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Dronedarone.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Dronedarone.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Dronedarone.Experimental
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Dronedarone.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Dronedarone.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Dronedarone.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Dronedarone.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Dronedarone.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Dronedarone.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Dronedarone.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Dronedarone.Approved, Illicit, Investigational
AlprenololDronedarone may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Dronedarone.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Dronedarone.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Dronedarone.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Dronedarone.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Dronedarone.Approved
AmiodaroneThe serum concentration of Dronedarone can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Dronedarone.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Dronedarone.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Dronedarone.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Dronedarone.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Dronedarone.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Dronedarone.Approved
AnagrelideAnagrelide may increase the QTc-prolonging activities of Dronedarone.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Dronedarone.Approved
Aop200704Dronedarone may increase the bradycardic activities of Aop200704.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Dronedarone.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
ApremilastThe metabolism of Apremilast can be decreased when combined with Dronedarone.Approved, Investigational
AprepitantThe serum concentration of Dronedarone can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Dronedarone.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Dronedarone.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Dronedarone.Approved, Investigational
ArotinololDronedarone may increase the bradycardic activities of Arotinolol.Approved
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
ArtemetherDronedarone may increase the QTc-prolonging activities of Artemether.Approved
AsenapineDronedarone may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Dronedarone.Approved, Withdrawn
AtazanavirThe serum concentration of Dronedarone can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololDronedarone may increase the bradycardic activities of Atenolol.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Dronedarone.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Dronedarone.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Dronedarone.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Dronedarone.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Dronedarone.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Dronedarone.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Dronedarone.Investigational
BedaquilineBedaquiline may increase the QTc-prolonging activities of Dronedarone.Approved
BefunololDronedarone may increase the bradycardic activities of Befunolol.Experimental
BendroflumethiazideBendroflumethiazide may increase the bradycardic activities of Dronedarone.Approved
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Dronedarone.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Dronedarone.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Dronedarone.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Dronedarone.Approved, Withdrawn
BeractantDronedarone may increase the bradycardic activities of Beractant.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Dronedarone.Approved, Vet Approved
BetaxololDronedarone may increase the bradycardic activities of Betaxolol.Approved
BevantololDronedarone may increase the bradycardic activities of Bevantolol.Approved
BexaroteneThe serum concentration of Dronedarone can be decreased when it is combined with Bexarotene.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Dronedarone.Approved
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Dronedarone.Approved
BisoprololDronedarone may increase the bradycardic activities of Bisoprolol.Approved
BoceprevirThe serum concentration of Dronedarone can be increased when it is combined with Boceprevir.Approved
BopindololDronedarone may increase the bradycardic activities of Bopindolol.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Dronedarone.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Dronedarone.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dronedarone.Approved
BretyliumBretylium may increase the bradycardic activities of Dronedarone.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Dronedarone.Approved
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Dronedarone.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Dronedarone.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Dronedarone.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Dronedarone.Approved
BucindololDronedarone may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Dronedarone.Approved
BudesonideThe metabolism of Budesonide can be decreased when combined with Dronedarone.Approved
BufuralolDronedarone may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Dronedarone.Approved, Investigational
BupranololDronedarone may increase the bradycardic activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Dronedarone.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Dronedarone can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Dronedarone.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Dronedarone.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Dronedarone.Approved, Investigational
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Dronedarone.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Dronedarone.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Dronedarone.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Dronedarone.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Dronedarone.Approved, Nutraceutical
CalfactantDronedarone may increase the bradycardic activities of Calfactant.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Dronedarone.Experimental
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Dronedarone.Approved
CaptoprilThe metabolism of Captopril can be decreased when combined with Dronedarone.Approved
CarbamazepineThe serum concentration of Dronedarone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Dronedarone.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Dronedarone.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Dronedarone.Approved
CarteololDronedarone may increase the bradycardic activities of Carteolol.Approved
CarvedilolDronedarone may increase the bradycardic activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Dronedarone.Approved, Investigational
CeliprololDronedarone may increase the bradycardic activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Dronedarone.Approved, Vet Approved
CeritinibDronedarone may increase the bradycardic activities of Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Dronedarone.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Dronedarone.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Dronedarone.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Dronedarone.Approved, Illicit
ChloroquineChloroquine may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Dronedarone.Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Dronedarone.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Dronedarone.Approved, Nutraceutical
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Dronedarone.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Dronedarone.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Dronedarone.Approved
CinacalcetThe metabolism of Dronedarone can be decreased when combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Dronedarone.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
CisaprideCisapride may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Dronedarone.Approved
CitalopramCitalopram may increase the QTc-prolonging activities of Dronedarone.Approved
ClarithromycinThe serum concentration of Dronedarone can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Dronedarone can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Dronedarone.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Dronedarone.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Dronedarone.Approved, Illicit
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Dronedarone.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Dronedarone.Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Dronedarone.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Dronedarone.Approved, Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Dronedarone.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Dronedarone.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Dronedarone.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Dronedarone.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Dronedarone.Approved, Illicit
ClotrimazoleThe metabolism of Dronedarone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Dronedarone.Approved
CobicistatThe serum concentration of Dronedarone can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Dronedarone.Approved
CocaineThe metabolism of Dronedarone can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Dronedarone.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Dronedarone.Approved
ConivaptanThe serum concentration of Dronedarone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Dronedarone.Approved
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Dronedarone.Approved
CrizotinibCrizotinib may increase the QTc-prolonging activities of Dronedarone.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Dronedarone.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Dronedarone.Approved, Investigational
CyclosporineThe serum concentration of Dronedarone can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Dronedarone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CytarabineThe metabolism of Cytarabine can be decreased when combined with Dronedarone.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Dronedarone.Approved
DabrafenibThe serum concentration of Dronedarone can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Dronedarone.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Dronedarone.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Dronedarone.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Dronedarone.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Dronedarone.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Dronedarone.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Dronedarone.Approved, Investigational
DarunavirThe serum concentration of Dronedarone can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Dronedarone.Approved
DasatinibThe serum concentration of Dronedarone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Dronedarone.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Dronedarone.Approved
DeferasiroxThe serum concentration of Dronedarone can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Dronedarone.Approved
DelavirdineThe metabolism of Dronedarone can be decreased when combined with Delavirdine.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Dronedarone.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Dronedarone.Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Dronedarone.Approved
DexamethasoneThe serum concentration of Dronedarone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Dronedarone.Approved, Illicit, Withdrawn
DexmedetomidineDexmedetomidine may increase the bradycardic activities of Dronedarone.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Dronedarone.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Dronedarone.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Dronedarone.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Dronedarone.Approved, Illicit, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Dronedarone.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Dronedarone.Approved, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Dronedarone.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dronedarone.Approved
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Dronedarone.Approved
DigoxinDigoxin may increase the atrioventricular blocking (AV block) activities of Dronedarone.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Dronedarone.Approved, Illicit
DihydroergotamineThe metabolism of Dronedarone can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Dronedarone.Illicit
DiltiazemDiltiazem may increase the atrioventricular blocking (AV block) activities of Dronedarone.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Dronedarone.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Dronedarone.Approved
DisopyramideDisopyramide may increase the QTc-prolonging activities of Dronedarone.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Dronedarone.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Dronedarone.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Dronedarone.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Dronedarone.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Dronedarone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Dronedarone.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Dronedarone.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Dronedarone.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Dronedarone.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Dronedarone.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Dronedarone.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Dronedarone.Approved, Investigational
DoxycyclineThe metabolism of Dronedarone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Dronedarone.Approved, Illicit
DroperidolDroperidol may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
DuloxetineThe metabolism of Dronedarone can be decreased when combined with Duloxetine.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Dronedarone.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Dronedarone.Approved
EfavirenzThe serum concentration of Dronedarone can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Dronedarone.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Dronedarone.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Dronedarone.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Dronedarone.Approved, Vet Approved
EncainideThe metabolism of Encainide can be decreased when combined with Dronedarone.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Dronedarone.Investigational
EnzalutamideThe serum concentration of Dronedarone can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Dronedarone.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Dronedarone.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Dronedarone.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Dronedarone.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Dronedarone.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Dronedarone.Approved
EribulinEribulin may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Dronedarone.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
EscitalopramEscitalopram may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Dronedarone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Dronedarone.Investigational
EsmololDronedarone may increase the bradycardic activities of Esmolol.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Dronedarone.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Dronedarone.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Dronedarone.Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Dronedarone.Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Dronedarone.Approved, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Dronedarone.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Dronedarone.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Dronedarone.Approved
EthanolThe metabolism of Ethanol can be decreased when combined with Dronedarone.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Dronedarone.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Dronedarone.Approved
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Dronedarone.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Dronedarone.Approved, Illicit
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Dronedarone.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Dronedarone.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Dronedarone.Approved, Investigational
EtravirineThe serum concentration of Dronedarone can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Dronedarone.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Dronedarone.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Dronedarone.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Dronedarone.Approved
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Dronedarone.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Dronedarone.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Dronedarone.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Dronedarone.Approved, Investigational
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Dronedarone.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Dronedarone.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dronedarone.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Dronedarone.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Dronedarone.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Dronedarone.Approved
FingolimodFingolimod may increase the arrhythmogenic activities of Dronedarone.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Dronedarone.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Dronedarone.Approved
FluconazoleFluconazole may increase the QTc-prolonging activities of Dronedarone.Approved
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Dronedarone.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Dronedarone.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Dronedarone.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Dronedarone.Approved, Illicit
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Dronedarone.Approved
FluoxetineFluoxetine may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
FlupentixolFlupentixol may increase the QTc-prolonging activities of Dronedarone.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Dronedarone.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Dronedarone.Approved, Illicit
FlutamideThe metabolism of Flutamide can be decreased when combined with Dronedarone.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Dronedarone.Approved
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Dronedarone.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Dronedarone.Approved
FluvoxamineThe metabolism of Dronedarone can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
FosamprenavirThe metabolism of Dronedarone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Dronedarone can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Dronedarone.Approved
FosphenytoinThe serum concentration of Dronedarone can be decreased when it is combined with Fosphenytoin.Approved
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Dronedarone.Approved, Investigational
Fusidic AcidThe serum concentration of Dronedarone can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Dronedarone.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Dronedarone.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Dronedarone.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Dronedarone.Approved
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Dronedarone.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
GlipizideThe metabolism of Glipizide can be decreased when combined with Dronedarone.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Dronedarone.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Dronedarone.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Dronedarone.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Dronedarone.Withdrawn
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Dronedarone.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Dronedarone.Approved
HaloperidolHaloperidol may increase the QTc-prolonging activities of Dronedarone.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Dronedarone.Approved, Vet Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Dronedarone.Approved
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Dronedarone.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Dronedarone.Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Dronedarone.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Dronedarone.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Dronedarone.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Dronedarone.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Dronedarone.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Dronedarone.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Dronedarone.Approved
IbutilideIbutilide may increase the QTc-prolonging activities of Dronedarone.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Dronedarone.Approved
IdelalisibThe serum concentration of Dronedarone can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Dronedarone resulting in a loss in efficacy.Approved
IloperidoneDronedarone may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Dronedarone.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Dronedarone.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Dronedarone.Approved, Investigational
IndacaterolIndacaterol may increase the QTc-prolonging activities of Dronedarone.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Dronedarone.Approved
IndenololDronedarone may increase the bradycardic activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Dronedarone can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Dronedarone.Approved, Investigational
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Dronedarone.Approved
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Dronedarone.Approved, Investigational
IsavuconazoniumThe metabolism of Dronedarone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
IsoniazidThe metabolism of Dronedarone can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Dronedarone.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Dronedarone.Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Dronedarone.Approved
ItraconazoleThe serum concentration of Dronedarone can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Dronedarone.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Dronedarone.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Dronedarone.Approved, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Dronedarone.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Dronedarone.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Dronedarone.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Dronedarone.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Dronedarone.Approved
KetoconazoleThe serum concentration of Dronedarone can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolDronedarone may increase the bradycardic activities of Labetalol.Approved
LacosamideDronedarone may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Dronedarone.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Dronedarone.Approved, Investigational
LanreotideDronedarone may increase the bradycardic activities of Lanreotide.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Dronedarone.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Dronedarone.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Dronedarone.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Dronedarone.Approved
LenvatinibLenvatinib may increase the QTc-prolonging activities of Dronedarone.Approved
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Dronedarone.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Dronedarone.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Dronedarone.Approved, Investigational
LevobunololDronedarone may increase the bradycardic activities of Levobunolol.Approved
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Dronedarone.Approved
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Dronedarone.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Dronedarone.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Dronedarone.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Dronedarone.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Dronedarone.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Dronedarone.Approved
LidocaineLidocaine may increase the arrhythmogenic activities of Dronedarone.Approved, Vet Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Dronedarone.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Dronedarone.Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Dronedarone.Approved
LithiumLithium may increase the QTc-prolonging activities of Dronedarone.Approved
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Dronedarone.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Dronedarone.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Dronedarone.Approved
LopinavirThe serum concentration of Dronedarone can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Dronedarone.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Dronedarone.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Dronedarone.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Dronedarone.Approved, Investigational
LucinactantDronedarone may increase the bradycardic activities of Lucinactant.Approved
LuliconazoleThe serum concentration of Dronedarone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Dronedarone can be decreased when it is combined with Lumacaftor.Approved
LumefantrineDronedarone may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Dronedarone.Approved
MacitentanThe metabolism of Macitentan can be decreased when combined with Dronedarone.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Dronedarone.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Dronedarone.Approved
MaravirocThe metabolism of Maraviroc can be decreased when combined with Dronedarone.Approved, Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Dronedarone.Approved, Vet Approved
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Dronedarone.Approved, Investigational
MefloquineMefloquine may increase the QTc-prolonging activities of Dronedarone.Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Dronedarone.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Dronedarone.Investigational, Withdrawn
MequitazineThe metabolism of Mequitazine can be decreased when combined with Dronedarone.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Dronedarone.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Dronedarone.Approved
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Dronedarone.Approved, Illicit
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Dronedarone.Illicit, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Dronedarone.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Dronedarone.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Dronedarone.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Dronedarone.Approved, Vet Approved
MethyldopaMethyldopa may increase the bradycardic activities of Dronedarone.Approved
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Dronedarone.Approved, Investigational
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Dronedarone.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Dronedarone.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Dronedarone.Approved, Illicit, Withdrawn
MetipranololDronedarone may increase the bradycardic activities of Metipranolol.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Dronedarone.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Dronedarone.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Dronedarone.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Dronedarone.Approved
MibefradilThe metabolism of Mibefradil can be decreased when combined with Dronedarone.Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Dronedarone.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
MinaprineThe metabolism of Minaprine can be decreased when combined with Dronedarone.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Dronedarone.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Dronedarone.Approved
MitotaneThe serum concentration of Dronedarone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Dronedarone.Approved, Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Dronedarone.Approved
ModafinilThe serum concentration of Dronedarone can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Dronedarone.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Dronedarone.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Dronedarone.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Dronedarone.Approved, Investigational
NadololDronedarone may increase the bradycardic activities of Nadolol.Approved
NafcillinThe serum concentration of Dronedarone can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Dronedarone.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Dronedarone.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Dronedarone.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Dronedarone.Approved, Investigational
NefazodoneThe serum concentration of Dronedarone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Dronedarone can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Dronedarone can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Dronedarone can be decreased when it is combined with Nevirapine.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Dronedarone.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Dronedarone.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Dronedarone.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Dronedarone.Approved
NilotinibDronedarone may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Dronedarone.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Dronedarone.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Dronedarone.Approved
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Dronedarone.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Dronedarone.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Dronedarone.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Dronedarone.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Dronedarone.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Dronedarone.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Dronedarone.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Dronedarone.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Dronedarone.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Dronedarone.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Dronedarone.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Dronedarone.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Dronedarone.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Dronedarone.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Dronedarone.Approved
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Dronedarone.Approved
OsimertinibThe serum concentration of Dronedarone can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Dronedarone.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Dronedarone.Approved
OxprenololDronedarone may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Dronedarone.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Dronedarone is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Dronedarone.Approved, Vet Approved
PalbociclibThe serum concentration of Dronedarone can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the QTc-prolonging activities of Dronedarone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Dronedarone.Approved, Investigational
PanobinostatThe serum concentration of Dronedarone can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Dronedarone.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Dronedarone.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Dronedarone.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Dronedarone.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Dronedarone.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Dronedarone.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Dronedarone.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Dronedarone.Approved
Peginterferon alfa-2bThe serum concentration of Dronedarone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololDronedarone may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentamidinePentamidine may increase the QTc-prolonging activities of Dronedarone.Approved
PentobarbitalThe serum concentration of Dronedarone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Dronedarone.Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Dronedarone.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Dronedarone.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Dronedarone.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Dronedarone.Approved, Investigational
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Dronedarone.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Dronedarone.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Dronedarone.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Dronedarone.Approved, Withdrawn
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Dronedarone.Approved
PhenobarbitalThe serum concentration of Dronedarone can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Dronedarone.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Dronedarone.Approved
PhenytoinThe serum concentration of Dronedarone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Dronedarone.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Dronedarone.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Dronedarone.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Dronedarone.Withdrawn
PindololDronedarone may increase the bradycardic activities of Pindolol.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Dronedarone.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Dronedarone.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Dronedarone.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Dronedarone.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Dronedarone.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Dronedarone.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Dronedarone.Approved
Poractant alfaDronedarone may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe serum concentration of Dronedarone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololDronedarone may increase the bradycardic activities of Practolol.Approved
PrasteroneThe metabolism of Prasterone can be decreased when combined with Dronedarone.Approved, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Dronedarone.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Dronedarone.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Dronedarone.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Dronedarone.Approved, Vet Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Dronedarone.Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Dronedarone.Approved, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Dronedarone.Approved, Vet Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Dronedarone.Approved
PrimidoneThe serum concentration of Dronedarone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideProcainamide may increase the QTc-prolonging activities of Dronedarone.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Dronedarone.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Dronedarone.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Dronedarone.Approved
PromazinePromazine may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Dronedarone.Approved
PropafenonePropafenone may increase the arrhythmogenic activities of Dronedarone.Approved
PropofolPropofol may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational, Vet Approved
PropranololDronedarone may increase the bradycardic activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Dronedarone.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Dronedarone.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Dronedarone.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Dronedarone.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Dronedarone.Approved, Illicit
QuetiapineQuetiapine may increase the QTc-prolonging activities of Dronedarone.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Dronedarone.Approved
QuinidineQuinidine may increase the QTc-prolonging activities of Dronedarone.Approved
QuinineQuinine may increase the QTc-prolonging activities of Dronedarone.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Dronedarone.Approved, Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Dronedarone.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Dronedarone.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Dronedarone.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Dronedarone.Approved, Investigational
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Dronedarone.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Dronedarone.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Dronedarone.Approved, Withdrawn
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Dronedarone.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Dronedarone.Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Dronedarone.Approved
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Dronedarone.Approved
RifabutinThe serum concentration of Dronedarone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Dronedarone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Dronedarone can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Dronedarone.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Dronedarone.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Dronedarone.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Dronedarone.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
RitonavirThe serum concentration of Dronedarone can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Dronedarone.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Dronedarone.Approved, Investigational
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Dronedarone.Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Dronedarone.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Dronedarone.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Dronedarone.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Dronedarone.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Dronedarone.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Dronedarone.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Dronedarone.Approved, Withdrawn
RuxolitinibRuxolitinib may increase the bradycardic activities of Dronedarone.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Dronedarone.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Dronedarone.Approved
SaquinavirThe serum concentration of Dronedarone can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Dronedarone.Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Dronedarone.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Dronedarone.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Dronedarone.Approved, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Dronedarone.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Dronedarone.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Dronedarone can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Dronedarone.Approved
SiltuximabThe serum concentration of Dronedarone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Dronedarone.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Dronedarone.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Dronedarone.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Dronedarone.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Dronedarone.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Dronedarone.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Dronedarone.Approved, Investigational
SorafenibSorafenib may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
SotalolDronedarone may increase the bradycardic activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Dronedarone.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Dronedarone.Experimental
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Dronedarone.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Dronedarone.Approved
St. John's WortThe serum concentration of Dronedarone can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Dronedarone can be increased when it is combined with Stiripentol.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Dronedarone.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Dronedarone.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Dronedarone.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Dronedarone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
SunitinibSunitinib may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Dronedarone.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Dronedarone.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Dronedarone.Approved
TacrolimusTacrolimus may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Dronedarone.Approved, Investigational
TadalafilThe metabolism of Tadalafil can be decreased when combined with Dronedarone.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Dronedarone resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Dronedarone.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Dronedarone.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Dronedarone.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Dronedarone.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Dronedarone.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Dronedarone.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Dronedarone.Investigational, Withdrawn
TelaprevirThe serum concentration of Dronedarone can be increased when it is combined with Telaprevir.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Dronedarone.Approved
TelithromycinThe serum concentration of Dronedarone can be increased when it is combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Dronedarone.Approved
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Dronedarone.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Dronedarone.Approved
TerbinafineThe metabolism of Dronedarone can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Dronedarone.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Dronedarone.Withdrawn
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Dronedarone.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Dronedarone.Approved, Investigational
TetrabenazineTetrabenazine may increase the QTc-prolonging activities of Dronedarone.Approved
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Dronedarone.Approved, Vet Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Dronedarone.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Dronedarone.Approved
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Dronedarone.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Dronedarone.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Dronedarone.Approved
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Dronedarone.Approved
TiclopidineThe metabolism of Dronedarone can be decreased when combined with Ticlopidine.Approved
TimololDronedarone may increase the bradycardic activities of Timolol.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Dronedarone.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Dronedarone.Approved
TipranavirThe metabolism of Dronedarone can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Dronedarone.Approved
TocilizumabThe serum concentration of Dronedarone can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Dronedarone.Approved, Investigational
TolterodineTolterodine may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Dronedarone.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Dronedarone.Approved, Investigational
ToremifeneToremifene may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Dronedarone.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Dronedarone.Approved, Investigational
TranylcypromineThe metabolism of Dronedarone can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Dronedarone.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Dronedarone.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Dronedarone.Approved, Vet Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Dronedarone.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Dronedarone.Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Dronedarone.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Dronedarone.Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Dronedarone.Approved
UdenafilThe metabolism of Udenafil can be decreased when combined with Dronedarone.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Dronedarone.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Dronedarone.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Dronedarone.Investigational, Withdrawn
VandetanibDronedarone may increase the QTc-prolonging activities of Vandetanib.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Dronedarone.Investigational
VardenafilVardenafil may increase the QTc-prolonging activities of Dronedarone.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Dronedarone.Approved
VemurafenibDronedarone may increase the QTc-prolonging activities of Vemurafenib.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Dronedarone.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Dronedarone.Approved
VerapamilVerapamil may increase the atrioventricular blocking (AV block) activities of Dronedarone.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Dronedarone.Investigational
VilanterolVilanterol may increase the QTc-prolonging activities of Dronedarone.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Dronedarone.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Dronedarone.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Dronedarone.Approved, Investigational
VincristineThe metabolism of Vincristine can be decreased when combined with Dronedarone.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Dronedarone.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Dronedarone.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Dronedarone.Approved
VoriconazoleThe serum concentration of Dronedarone can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Dronedarone.Approved
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Dronedarone.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Dronedarone.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Dronedarone.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Dronedarone.Approved
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Dronedarone.Approved, Illicit, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Dronedarone.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Dronedarone.Approved, Investigational, Withdrawn
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Dronedarone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Dronedarone.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Dronedarone.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Dronedarone.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Dronedarone.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Dronedarone.Approved, Investigational
Food Interactions
  • Absorption of dronedarone increases 3-fold if taken with food especially if meal is high in fat content
  • Do not take dronedarone with grapefruit juice. Grapefruit juice is a potent CYP3A4 inhibitor which will increase serum concentrations of dronedarone threefold
References
Synthesis Reference

Arie Gutman, Gennadi Nisnevich, Lev Yudovitch, “Process for the preparation of dronedarone.” U.S. Patent US20050049302, issued March 03, 2005.

US20050049302
General References
  1. Dale KM, White CM: Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007 Apr;41(4):599-605. Epub 2007 Mar 27. [PubMed:17389667 ]
  2. Iwamoto T, Watanabe Y, Kita S, Blaustein MP: Na+/Ca2+ exchange inhibitors: a new class of calcium regulators. Cardiovasc Hematol Disord Drug Targets. 2007 Sep;7(3):188-98. [PubMed:17896959 ]
  3. Celestino D, Medei E, Moro S, Elizari MV, Sicouri S: Acute in vitro effects of dronedarone, an iodine-free derivative, and amiodarone, on the rabbit sinoatrial node automaticity: a comparative study. J Cardiovasc Pharmacol Ther. 2007 Sep;12(3):248-57. [PubMed:17875953 ]
  4. Pamukcu B, Lip GY: Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmacodynamics and clinical practice. Expert Opin Pharmacother. 2011 Jan;12(1):131-40. doi: 10.1517/14656566.2011.540800. Epub 2010 Dec 2. [PubMed:21126199 ]
  5. De Ferrari GM, Dusi V: Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf. 2012 Nov;11(6):1023-45. doi: 10.1517/14740338.2012.722994. Epub 2012 Sep 13. [PubMed:22971242 ]
External Links
ATC CodesC01BD07
AHFS Codes
  • 24:04.04.20
PDB EntriesNot Available
FDA labelDownload (606 KB)
MSDSDownload (115 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9156
Caco-2 permeable-0.6057
P-glycoprotein substrateSubstrate0.6265
P-glycoprotein inhibitor IInhibitor0.7879
P-glycoprotein inhibitor IINon-inhibitor0.5218
Renal organic cation transporterNon-inhibitor0.7334
CYP450 2C9 substrateNon-substrate0.7339
CYP450 2D6 substrateNon-substrate0.7682
CYP450 3A4 substrateSubstrate0.6963
CYP450 1A2 substrateNon-inhibitor0.5487
CYP450 2C9 inhibitorInhibitor0.6209
CYP450 2D6 inhibitorNon-inhibitor0.8299
CYP450 2C19 inhibitorNon-inhibitor0.5319
CYP450 3A4 inhibitorNon-inhibitor0.5198
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8288
Ames testNon AMES toxic0.5248
CarcinogenicityNon-carcinogens0.6132
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6273 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8036
hERG inhibition (predictor II)Inhibitor0.8051
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral400 mg
Tablet, film coatedOral400 mg/1
Tablet, film coatedOral400 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2047773 No2000-09-122011-07-24Canada
CA2294812 No2009-09-292018-06-19Canada
US5223510 No1996-07-262016-07-26Us
US7323493 No1998-06-192018-06-19Us
US8318800 No1998-06-192018-06-19Us
US8410167 No2009-04-162029-04-16Us
US8602215 No2011-06-302031-06-30Us
US9107900 No2009-04-162029-04-16Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityInsoluble FDA label
logP7.346MSDS
Predicted Properties
PropertyValueSource
Water Solubility0.00201 mg/mLALOGPS
logP6.46ALOGPS
logP5.28ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)9.08ChemAxon
pKa (Strongest Basic)9.79ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area88.85 Å2ChemAxon
Rotatable Bond Count17ChemAxon
Refractivity158.13 m3·mol-1ChemAxon
Polarizability66.05 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as sulfanilides. These are organic aromatic compounds containing a sulfanilide moiety, with the general structure RS(=O)(=O)NC1=CC=CC=C1.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassSulfanilides
Direct ParentSulfanilides
Alternative Parents
Substituents
  • Sulfanilide
  • Benzofuran
  • Acetophenone
  • Aryl ketone
  • 3-aroylfuran
  • Phenol ether
  • Benzoyl
  • Alkyl aryl ether
  • Heteroaromatic compound
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Furan
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Oxacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Dale KM, White CM: Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007 Apr;41(4):599-605. Epub 2007 Mar 27. [PubMed:17389667 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Dale KM, White CM: Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007 Apr;41(4):599-605. Epub 2007 Mar 27. [PubMed:17389667 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Dale KM, White CM: Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007 Apr;41(4):599-605. Epub 2007 Mar 27. [PubMed:17389667 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Dale KM, White CM: Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007 Apr;41(4):599-605. Epub 2007 Mar 27. [PubMed:17389667 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Dale KM, White CM: Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007 Apr;41(4):599-605. Epub 2007 Mar 27. [PubMed:17389667 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Dale KM, White CM: Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007 Apr;41(4):599-605. Epub 2007 Mar 27. [PubMed:17389667 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Dale KM, White CM: Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007 Apr;41(4):599-605. Epub 2007 Mar 27. [PubMed:17389667 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Iwamoto T, Watanabe Y, Kita S, Blaustein MP: Na+/Ca2+ exchange inhibitors: a new class of calcium regulators. Cardiovasc Hematol Disord Drug Targets. 2007 Sep;7(3):188-98. [PubMed:17896959 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1F gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1F
Uniprot ID:
O60840
Molecular Weight:
220675.9 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1S
Uniprot ID:
Q13698
Molecular Weight:
212348.1 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB1
Uniprot ID:
Q02641
Molecular Weight:
65712.995 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB2
Uniprot ID:
Q08289
Molecular Weight:
73579.925 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB3
Uniprot ID:
P54284
Molecular Weight:
54531.425 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB4
Uniprot ID:
O00305
Molecular Weight:
58168.625 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient.
Gene Name:
SCN1A
Uniprot ID:
P35498
Molecular Weight:
228969.49 Da
References
  1. Lalevee N, Nargeot J, Barrere-Lemaire S, Gautier P, Richard S: Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. J Cardiovasc Electrophysiol. 2003 Aug;14(8):885-90. [PubMed:12890054 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Potassium ion leak channel activity
Specific Function:
Ion channel that contributes to passive transmembrane potassium transport (PubMed:23169818). Reversibly converts between a voltage-insensitive potassium leak channel and a voltage-dependent outward rectifying potassium channel in a phosphorylation-dependent manner (PubMed:11319556). In astrocytes, forms mostly heterodimeric potassium channels with KCNK1, with only a minor proportion of function...
Gene Name:
KCNK2
Uniprot ID:
O95069
Molecular Weight:
47092.215 Da
References
  1. Schmidt C, Wiedmann F, Schweizer PA, Becker R, Katus HA, Thomas D: Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels. Naunyn Schmiedebergs Arch Pharmacol. 2012 Oct;385(10):1003-16. doi: 10.1007/s00210-012-0780-9. Epub 2012 Jul 13. [PubMed:22790794 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Schafer JA, Kjesbo NK, Gleason PP: Dronedarone: current evidence and future questions. Cardiovasc Ther. 2010 Spring;28(1):38-47. doi: 10.1111/j.1755-5922.2009.00112.x. [PubMed:20074258 ]
  2. De Ferrari GM, Dusi V: Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf. 2012 Nov;11(6):1023-45. doi: 10.1517/14740338.2012.722994. Epub 2012 Sep 13. [PubMed:22971242 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Dorian P: Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation. J Cardiovasc Pharmacol Ther. 2010 Dec;15(4 Suppl):15S-8S. doi: 10.1177/1074248410367792. Epub 2010 May 14. [PubMed:20472816 ]
  2. Schafer JA, Kjesbo NK, Gleason PP: Dronedarone: current evidence and future questions. Cardiovasc Ther. 2010 Spring;28(1):38-47. doi: 10.1111/j.1755-5922.2009.00112.x. [PubMed:20074258 ]
  3. De Ferrari GM, Dusi V: Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf. 2012 Nov;11(6):1023-45. doi: 10.1517/14740338.2012.722994. Epub 2012 Sep 13. [PubMed:22971242 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. De Ferrari GM, Dusi V: Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf. 2012 Nov;11(6):1023-45. doi: 10.1517/14740338.2012.722994. Epub 2012 Sep 13. [PubMed:22971242 ]
  2. Schafer JA, Kjesbo NK, Gleason PP: Dronedarone: current evidence and future questions. Cardiovasc Ther. 2010 Spring;28(1):38-47. doi: 10.1111/j.1755-5922.2009.00112.x. [PubMed:20074258 ]
Comments
comments powered by Disqus
Drug created on October 18, 2007 17:47 / Updated on December 08, 2016 11:11